San Francisco, California
QED Therapeutics, a subsidiary of BridgeBio Services, focuses on precision medicine for FGFR-driven cancers and diseases. The company’s first therapy, TRUSELTIQ (infigratinib), is an orally administered FGFR1-3 tyrosine kinase inhibitor that was recently approved by the US FDA for the treatment of patients with previously-treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement. We are also evaluating infigratinib for the treatment of other FGFR-driven cancers as well as for the treatment of achondroplasia and other skeletal dysplasias.
QED is derived from the Latin “Quod Erat Demonstrandum” -Thus, It Has Been Proven. Our business is inspired by our values:
PUT PATIENTS FIRST
LET SCIENCE SPEAK
EVERY MINUTE COUNTS
BE RADICALLY TRANSPARENT
FGFR=fibroblast growth factor receptor.
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs. Founded in 2015 by a team of industry veterans, the company has built a portfolio of 20 transformative drugs ranging from pre-clinical to late-stage development in multiple therapeutic areas including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. The company’s focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have offices in San Francisco, Palo Alto, Boston, New York, and Raleigh, with small satellites in other parts of the country.
To learn more, visit us at |
Who You Are:
QED is expanding its business development and operations team and is seeking a teammate who will assist in our worldwide launch, partnership development, and corporate strategy. In this unique role, you will be supporting the strategy, execution, and management of partnership transactions, as well as generating analysis to support decision-making across the organization. You will be able to directly see the impact your work is having on getting infigratinib to patients.
Education, Experience & Skills Requirements:
What We Offer:
We will not accept unsolicited resumes from agencies. Please do not send agency resumes to our website or BridgeBio and affiliating employees.